Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.3B | $3.9B | +10.42% |
Cost of Revenue | $1.64B | $1.52B | +8.27% |
Gross Profit | $2.66B | $2.38B | +11.80% |
Operating Income | $1.36B | $1.13B | +20.53% |
Net Income | $1.06B | $887.87M | +19.33% |
EPS (Basic) | $13.17 | $10.77 | +22.28% |
EPS (Diluted) | $13.08 | $10.67 | +22.59% |
R&D Expense | $251.21M | $219.79M | +14.29% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $3.35B | $3.29B | +1.74% |
Current Assets | $1.41B | $1.4B | +1.00% |
Total Liabilities | $1.75B | $1.7B | +2.78% |
Current Liabilities | $1.15B | $1.07B | +7.58% |
Stockholders' Equity | $1.61B | $1.6B | +0.63% |
Cash & Equivalents | $180.07M | $288.27M | -37.53% |
Long-Term Debt | $450M | $617.8M | -27.16% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.18B | $929M | +27.21% |
Investing Cash Flow | $-136.24M | $-207.06M | +34.20% |
Financing Cash Flow | $-1.16B | $-878.07M | -32.67% |
Share Buybacks | $1.22B | $837.03M | +45.39% |
D&A | $145.18M | $129.94M | +11.73% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 61.8% | 61.0% | +0.76% |
Operating Margin | 31.6% | 29.0% | +2.65% |
Net Margin | 24.6% | — | — |
ROE | 66.0% | — | — |
ROA | 31.6% | — | — |
Current Ratio | $1.231 | — | — |
Debt to Equity | $1.087 | — | — |
IDXX reported strong financial performance in 2025 with significant growth in revenue and net income, driven by improved operating efficiency and strategic investments.
IDXX achieved a 10.4% increase in revenue, driven by strong demand for its diagnostic products and services.
Source: Source: 10-K Income Statement
Operating income rose by 20.5% due to improved cost management and operational efficiencies.
Source: Source: 10-K Income Statement
Increased R&D spending by 14.3% reflects the company's commitment to innovation and long-term growth.
Source: Source: 10-K Income Statement
The company experienced a significant decrease in cash and equivalents by 37.5%, which could impact liquidity management.
Source: Source: 10-K Balance Sheet
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Health Care